Listen on the go
CORRECT!
Next question
touchHAEMATOLOGY touchHAEMATOLOGY

Trending Activities
Leukaemia
touchEXPERT OPINIONS
Higher-risk MDS and AML: How new guidelines are changing diagnosis, classification and management
Prof. Andrew Wei, Prof. Agnieszka Wierzbowska, Prof. Gert Ossenkoppele Translations available:
Watch Time: 33 mins

Experts answer questions with in-depth advice on the current clinical landscape and how new guidelines might impact regional clinical practice. Useful tips below will show how to navigate the activity.

Learning objectives
Learning Objectives
  • Describe the clinical presentation and the diagnostic process for MDS and AML
  • Demonstrate how the pathophysiology of MDS and AML determines disease classification
  • Outline the updated risk stratification guidelines for MDS and AML and the implications for patient management
touchSATELLITE SYMPOSIUM
Tackling unmet needs in chronic myeloid leukaemia: What’s next in the treatment algorithm?
Prof. Susanne Saussele, Prof. Massimo Breccia, Prof. Valentín García Gutiérrez
Watch Time: 62 mins

Three experts consider unmet needs in chronic myeloid leukaemia and how new and emerging treatments may help address them.

Learning objectives
Learning Objectives
  • Summarize the rationale for new agents in CML in light of treatment safety considerations
  • Discuss the unmet needs for patients with CML in later lines of therapy and how new agents may address these
  • Explain how new and emerging agents may affect the treatment paradigm for patients with CML

All Activities

View all Education activities

Leukaemia
Watch Time: 33 mins
touchEXPERT OPINIONS
Higher-risk MDS and AML: How new guidelines are changing diagnosis, classification and management
Prof. Andrew Wei, Prof. Agnieszka Wierzbowska, Prof. Gert Ossenkoppele Translations available:

Experts answer questions with in-depth advice on the current clinical landscape and how new guidelines might impact regional clinical practice. Useful tips below will show how to navigate the activity.

Learning objectives
Learning Objectives
  • Describe the clinical presentation and the diagnostic process for MDS and AML
  • Demonstrate how the pathophysiology of MDS and AML determines disease classification
  • Outline the updated risk stratification guidelines for MDS and AML and the implications for patient management
Watch Time: 62 mins
touchSATELLITE SYMPOSIUM
Tackling unmet needs in chronic myeloid leukaemia: What’s next in the treatment algorithm?
Prof. Susanne Saussele, Prof. Massimo Breccia, Prof. Valentín García Gutiérrez

Three experts consider unmet needs in chronic myeloid leukaemia and how new and emerging treatments may help address them.

Learning objectives
Learning Objectives
  • Summarize the rationale for new agents in CML in light of treatment safety considerations
  • Discuss the unmet needs for patients with CML in later lines of therapy and how new agents may address these
  • Explain how new and emerging agents may affect the treatment paradigm for patients with CML
Watch Time: 29 mins
touchIN CONVERSATION
Selecting the optimal treatment for patients with chronic myeloid leukaemia after two prior lines of therapy
Prof. Simona Soverini, Dr Daniela Žáčková

Two specialists in chronic myeloid leukaemia (CML) discuss the mechanisms of action and latest data for current and emerging treatments and how they may impact the management of CML after two prior lines of therapy.

Learning objectives
Learning Objectives
  • Discuss the treatment for patients with CML after two prior lines of therapy in clinical practice
  • Recall the latest clinical trial data for new and emerging treatments for patients with CML
  • Evaluate the possible impact of new and emerging treatments on the management of patients with CML after two prior lines of therapy
Watch Time: 37 mins
touchMDT
Facing clinical challenges associated with paroxysmal nocturnal haemoglobinuria
Prof. Régis Peffault de Latour, Dr Will Evans, Ms Jess Ratcliffe

Watch a leading haematologist, a primary care physician and a patient with paroxysmal nocturnal haemoglobinuria (PNH) share their perspectives on the clinical challenges associated with PNH.

Learning objectives
Learning Objectives
  • Summarize the signs and symptoms of PNH and how these inform the clinical diagnosis
  • Explain the benefits and limitations of current and emerging complement inhibitor therapies for PNH
  • Explain the burden of PNH and impact on patients’ quality of life
Watch Time: 47 mins
touchEXPERT OPINIONS
Advancing the management of MDS and AML: Novel immune-based approaches
Prof. Dr. med. Uwe Platzbecker, Prof. Agnieszka Wierzbowska, Prof. Valeria Santini

Three experts consider the potential of immune-based strategies to treat MDS and AML.

Learning objectives
Learning Objectives
  • Discuss the role of immune dysregulation in the pathophysiology and progression of MDS and AML
  • Recall data on the use of immune checkpoint inhibitors in the management of MDS and AML
  • Describe the mechanisms of action and clinical trial data for emerging investigational agents targeting immune dysfunction in MDS and AML
Watch Time: 56 mins
touchCONGRESS
Higher-risk MDS and newly diagnosed AML: What are the latest developments from EHA 2022?
Prof. Michael Heuser, Dr Yishai Ofran, Dr Esther Oliva

Watch this two-part activity exploring recent developments in the treatment of higher-risk MDS and newly diagnosed AML. Filmed following the EHA 2022 Hybrid Congress.

Learning objectives
Learning Objectives
  • Summarize the data for emerging therapeutic strategies for patients with HR-MDS
  • Recall the data for emerging treatments for patients with newly diagnosed AML who are unfit for intensive chemotherapy
  • Discuss advances in risk assessment and treatment personalization for patients with HR-MDS or AML
Watch Time: 65 mins
touchCONGRESS
Current and emerging treatments for chronic myeloid leukemia: What have we learnt from EHA Hybrid Conference 2022?
Prof. Giuseppe Saglio, Prof. Dietger Walter, Niederwieser, Prof. Francois-Xavier Mahon

Watch this two-part activity exploring recent data on current and emerging treatments for CML. Filmed following the EHA Hybrid Conference 2022.

Learning objectives
Learning Objectives
  • Recall the latest data relating to current therapeutic agents for patients with CML
  • Summarize the latest data for investigational therapeutic agents for patients with CML
  • Discuss how the latest data for current and emerging treatments for CML could affect the management of patients in clinical practice
Watch Time: 46 mins
touchMDT
Multidisciplinary management of chronic myeloid leukaemia in the later-line setting: A holistic approach
Prof. Dr. Andreas Hochhaus, Dr Kim Bee Tan, Mr Johan De Munter, Ms Jelena Čugurović

Watch chronic myeloid leukaemia (CML) specialists within a multidisciplinary team, plus a CML patient advocate, discuss the later-line management of CML.

Learning objectives
Learning Objectives
  • Discuss the later-line treatment of chronic myeloid leukaemia, including T315I mutation-positive disease
  • Manage the toxicities associated with tyrosine kinase inhibitor treatments for chronic myeloid leukaemia
  • Recognize the impact of tyrosine kinase inhibitors on quality of life for patients with chronic myeloid leukaemia
Watch Time: 61 mins
touchCONGRESS
Advancing the treatment of MDS and AML: An update from ASH 2021
Prof. Pierre Fenaux, Prof. Andrew Wei, Dr Esther Oliva

Watch this two-part activity exploring recent data on new and emerging treatments for patients with higher-risk MDS and newly diagnosed AML, filmed following the ASH 2021 Annual Meeting & Exposition.

Learning objectives
Learning Objectives
  • Recall the latest data for emerging therapeutic strategies for patients with HR-MDS
  • Summarize data for emerging treatments for patients with AML who are unfit for intensive chemotherapy
  • Discuss advances in treatment personalization and monitoring for patients with HR-MDS or AML
Watch Time: 38 mins
touchEXPERT OPINIONS
Managing adverse events associated with BCMA-targeting agents in multiple myeloma: The role of the multidisciplinary team
Miss Simona Degli Esposti, Prof. Ibrahim Yakoub-Agha, Dr Paula Rodríguez-Otero

Watch leading experts review adverse event management with BCMA-targeting multiple myeloma therapies, and consider the role of the multidisciplinary team.

Learning objectives
Learning Objectives
  • Use the most appropriate management strategy for patients experiencing ocular toxicity following treatment with a BCMA-targeting antibody-drug conjugate
  • Discuss the adverse events associated with BCMA-targeting CAR T-cell therapies, and how they can be managed
  • Recognize the importance of the multidisciplinary care team in the management of patients receiving a BCMA-targeting therapy for multiple myeloma
Watch Time: 64 mins
touchCONGRESS
Exploring the latest data on new and emerging treatments for the improvement of outcomes in higher-risk MDS and newly diagnosed AML
Prof. Uwe Platzbecker, Prof. Valeria Santini, Prof. Andrew Wei

Watch this two-part activity exploring recent developments around the treatment of higher-risk MDS and newly diagnosed AML. Filmed following the EHA2021 Virtual Congress.

Learning objectives
Learning Objectives
  • Recall the mechanisms of action and key clinical data for emerging treatments for higher-risk MDS
  • Evaluate current treatments and novel approaches for newly diagnosed AML, including management options when intensive induction therapy is not suitable
  • Discuss the current and future potential of immunotherapy and the use of measurable residual disease (MRD) monitoring in MDS and AML
Watch Time: 64 mins
touchCONGRESS
Advances in the role of BCMA-targeting agents in multiple myeloma: An update from the EHA Congress 2021
Dr María-Victoria Mateos, Dr Heather Sutherland, Prof. Dr. Niels van de Donk

Watch this two-part activity exploring recent data for BCMA-targeting agents in multiple myeloma. Filmed following the European Hematology Association 2021 Virtual Congress.

Learning objectives
Learning Objectives
  • Recall efficacy data for BCMA-targeting agents in the treatment of multiple myeloma
  • Describe the safety data for BCMA-targeting agents in the treatment of multiple myeloma
  • Discuss how the latest data on BCMA-targeting agents may affect the management of patients with multiple myeloma
Watch Time: 29 mins
touchPANEL DISCUSSION
Integrating BCMA-targeting agents into the treatment pathway for relapsed/refractory multiple myeloma
Dr Francesca Gay, Prof. Meletios Dimopoulos, Prof. Dr. Hermann Einsele

Watch a panel of experts discuss the use of BCMA-targeting agents in the treatment of relapsed/refractory multiple myeloma.

Learning objectives
Learning Objectives
  • Discuss the potential of BCMA-targeting agents to improve outcomes for patients with relapsed/refractory multiple myeloma
  • Identify patients with relapsed/refractory multiple myeloma who may benefit from treatment with a BCMA-targeting agent
  • Use strategies to monitor for and manage the adverse events associated with BCMA-targeting agents
Watch Time: 45 mins
touchPANEL DISCUSSION
What is the current state of play of CAR T-cell therapy for B-cell malignancies? Focus on patient selection, safety and new indications
Prof. Christian Chabannon, Prof. Chiara Bonini, Prof. Dr. Peter Borchmann

Learn about patient selection for chimeric antigen receptor (CAR) T-cell therapy, adverse event management and the latest developments in CAR T-cell therapies for B-cell malignancies from experts in the field.

Learning objectives
Learning Objectives
  • Describe patients who may be eligible for treatment with CAR T-cell therapy
  • Review the management of adverse events associated with CAR T-cell therapy
  • Discuss how CAR T-cell therapy might impact the treatment pathway for new indications
Watch Time: 39 mins
touchTALKS
Exploring the changing landscape in Waldenström’s macroglobulinaemia: How will emerging BTK inhibitors alter patient outcomes?
Dr Alessandra Tedeschi

Join Dr Alessandra Tedeschi as she highlights the latest data on second-generation Bruton’s tyrosine kinase inhibitors in the management of Waldenström’s macroglobulinaemia.

Learning objectives
Learning Objectives
  • Evaluate the new and emerging efficacy data for second-generation BTK inhibitors in patients with WM
  • Summarize the adverse events associated with second-generation BTK inhibitors
  • Review current management recommendations for people with Waldenström’s macroglobulinaemia
Watch Time: 32 mins
touchPANEL DISCUSSION
CAR-T in clinical practice: Navigating the patient journey from referral to long-term follow-up
Prof. Mohamad Mohty, Dr John Kuruvilla, Dr Robin Sanderson

Watch a panel of internationally renowned experts discuss the use of chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma (DLBCL).

Learning objectives
Learning Objectives
  • Recall the latest real-world evidence for the use of chimeric antigen receptor T-cell (CAR-T) therapy in patients with diffuse large B-cell lymphoma (DLBCL)
  • Describe which patients with DLBCL should be referred for assessment for CAR-T therapy and discuss the importance of early referral
  • Discuss the roles of referral centres and treatment centres in patient management, in particular long-term follow up of patients
Watch Time: 19 mins
touchEXPERT OPINIONS
Paroxysmal nocturnal hemoglobinuria: from biology to bedside
Prof. Régis Peffault de Latour

Prof. Régis Peffault de Latour (French Reference Center for Aplastic Anemia and PNH, Saint-Louis Hospital, Paris, France) appraises the most important recent and emerging data, and discusses their potential impact on the clinical management of patients living with PNH.

Learning objectives
Learning Objectives
  • Discuss the current treatment landscape for PNH
  • Describe the unmet medical needs for PNH with respect to current treatment options
  • Summarize the evolving treatment landscape and future approaches for the management of PNH
Watch Time: 38 mins
touchPANEL DISCUSSION
Have the next generation of BTK inhibitors come of age for the treatment of Waldenström’s macroglobulinemia?
Dr Roger Owen, Prof. Veronique LeBlond, Prof. Christian Buske

Watch a panel of internationally renowned Waldenström’s macroglobulinemia experts discuss the clinical utility of second-generation Bruton’s tyrosine kinase (BTK) inhibitors, and their potential impact on the current treatment paradigm.

Learning objectives
Learning Objectives
  • Identify the pharmacokinetic and pharmacodynamic attributes of second-generation BTK inhibitors
  • Discuss emerging clinical data with second-generation BTK inhibitors in Waldenström’s macroglobulinemia (WM)
  • Discuss the potential of second-generation agents to improve patients’ outcomes and experiences in WM
IME
Education activities are developed by touchIME for touchHAEMATOLOGY.

Our education resources are developed in collaboration with our well established peer-reviewed medical journals, our Editorial Board members and partnerships with major medical societies, with a clear commitment to high-quality independent education.

Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72